Novavax

NVAX NASDAQ
4.610
-0.030
-0.65%
After Hours: 4.500 -0.11 -2.39% 19:31 07/19 EDT
Open
4.700
Prev Close
4.640
High
4.700
Low
4.500
Volume
411.42K
Avg Vol (3M)
826.89K
52 Week High
51.60
52 Week Low
4.380
% Turnover
1.75%
Market Cap
108.21M
1D
5D
1M
3M
1Y
5Y

Company Profile

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
MORE >

Recently

Name
Price
%Change